Literature DB >> 22889170

Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Raymond J Bergeron1, Jan Wiegand, Neelam Bharti, James S McManis.   

Abstract

Desferrithiocin (DFT, 1) is a very efficient iron chelator when given orally. However, it is severely nephrotoxic. Structure-activity studies with 1 demonstrated that removal of the aromatic nitrogen to provide desazadesferrithiocin (DADFT, 2) and introduction of either a hydroxyl group or a polyether fragment onto the aromatic ring resulted in orally active iron chelators that were much less toxic than 1. The purpose of the current study was to determine if a comparable reduction in renal toxicity could be achieved by performing the same structural manipulations on 1 itself. Accordingly, three DFT analogues were synthesized. The iron-clearing efficiency and ferrokinetics were evaluated in rats and primates; toxicity assessments were carried out in rodents. The resulting DFT ligands demonstrated a reduction in toxicity that was equivalent to that of the DADFT analogues and presented with excellent iron-clearing properties.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889170      PMCID: PMC3583384          DOI: 10.1021/jm300509y

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  54 in total

Review 1.  Microbial iron transport: iron acquisition by pathogenic microorganisms.

Authors:  B R Byers; J E Arceneaux
Journal:  Met Ions Biol Syst       Date:  1998

Review 2.  Function and regulation of transferrin and ferritin.

Authors:  P Ponka; C Beaumont; D R Richardson
Journal:  Semin Hematol       Date:  1998-01       Impact factor: 3.851

3.  Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to oxidize alpha-amino acids to a family of reactive aldehydes. Mechanistic studies identifying labile intermediates along the reaction pathway.

Authors:  S L Hazen; A d'Avignon; M M Anderson; F F Hsu; J W Heinecke
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

4.  Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

Authors:  A V Hoffbrand; F AL-Refaie; B Davis; N Siritanakatkul; B F Jackson; J Cochrane; E Prescott; B Wonke
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  HBED: A potential alternative to deferoxamine for iron-chelating therapy.

Authors:  R J Bergeron; J Wiegand; G M Brittenham
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

Review 6.  Iron-chelating therapy and the treatment of thalassemia.

Authors:  N F Olivieri; G M Brittenham
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

7.  Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.

Authors:  Raymond J Bergeron; Jan Wiegand; William R Weimar; James S McManis; Richard E Smith; Khalil A Abboud
Journal:  Chirality       Date:  2003-08       Impact factor: 2.437

8.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

Authors:  N F Olivieri; G M Brittenham; C E McLaren; D M Templeton; R G Cameron; R A McClelland; A D Burt; K A Fleming
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

9.  Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.

Authors:  R J Bergeron; J Wiegand; M Wollenweber; J S McManis; S E Algee; K Ratliff-Thompson
Journal:  J Med Chem       Date:  1996-04-12       Impact factor: 7.446

Review 10.  Long-term therapy with deferiprone.

Authors:  N F Olivieri
Journal:  Acta Haematol       Date:  1996       Impact factor: 2.195

View more
  2 in total

1.  Growth Inhibition of a Novel Iron Chelator, DpdtC, against Hepatoma Carcinoma Cell Lines Partly Attributed to Ferritinophagy-Mediated Lysosomal ROS Generation.

Authors:  Tengfei Huang; Yanjie Sun; Yongli Li; Tingting Wang; Yun Fu; Cuiping Li; Changzheng Li
Journal:  Oxid Med Cell Longev       Date:  2018-08-05       Impact factor: 6.543

Review 2.  Desferrithiocin: a search for clinically effective iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.